Hoth Therapeutics (HOTH) has entered into an exclusive patent license agreement with the U.S. Department of Veterans Affairs, providing the company with exclusive rights to a jointly owned patent portfolio co-developed by the the U.S. Department of Veterans Affairs and Emory University. The licensed technology centers on Glial Cell Line-Derived Neurotrophic Factor, Obesity, and Obesity-Related Diseases and Conditions. Hoth Therapeutics will have exclusive rights to develop, market, and commercialize products and processes derived from the licensed patents.
Hoth has also entered into an agreement to protect its intellectual property by signing an LOI to acquire additional provisional patent protection for its therapeutic HT-001.
Shares of Hoth Therapeutics are up 9% in pre-market trade on Thursday.
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.